ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business

Takeda transferring some drug development to joint venture

Diabetes, obesity, high blood pressure among fields new unit will cover

Takeda Pharmaceutical's Shonan Research Center in Japan.

TOKYO -- Takeda Pharmaceutical has formed a 10 billion yen ($87.2 million) drug development company with two partners, allowing the Japanese company to concentrate resources on three core areas.

The public-private Innovation Network Corp. of Japan holds the largest share of the new company, called Scohia Pharma, at 70.5%. Takeda owns a 19.5% stake, while Medipal Holdings has the remaining 10%, according to Tuesday's announcement.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more